Lung cancer Patients' sleep troubles under the microscope
NCT ID NCT06495346
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study explored sleep disorders in 37 adults with non-small cell lung cancer. Participants filled out questionnaires about their sleep, symptoms, mood, and quality of life. The goal was to create a guide to help doctors diagnose and treat sleep issues in this group, ultimately improving patient care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a decision tree that helps doctors better diagnose and treat sleep problems in lung cancer patients, improving their quality of life.
- What could go wrong
- This is a small, completed exploratory study with only 37 participants. The findings may not apply to all lung cancer patients, and the decision tree needs further testing before it can be used in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
37 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a diagnosis of non-small cell lung cancer followed and treated by the Oncopneumology Department of the Nouvel Hôpital Civil in Strasbourg
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient aged 18 and over. * Being monitored and treated for non-small cell lung cancer. * With or without ongoing cancer-specific treatment. With no neurocognitive impairment (MoCA test score ≥26/30). * With a clinically assessed life expectancy of more than 3 months (Royal Marsden Hospital 0-1) and general health (ECOG \<2). * Able to understand the study documents written in French * Able to complete the study questionnaires written in French. * Contactable by telephone throughout the study * Affiliated to a social security scheme or entitled beneficiary * Not opposed to taking part in the study Exclusion Criteria: * Patient refusing to take part in the study * With a mental illness of the psychosis type monitored and treated prior to the study * Patient under guardianship or curatorship * Patient under court protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HUS
Strasbourg, Grand Est, 67117, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?
- Two-Drug combo takes aim at Hard-to-Treat lung cancer